CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event

<br /> CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event<br />

PR Newswire


Live video webcast on

Wednesday, January 18


th

at

10:00 AM ET



HOUSTON


,


January 5, 2023


/PRNewswire/ —

CNS Pharmaceuticals, Inc.

(NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that


John Climaco

, Chief Executive Officer

of CNS Pharmaceuticals will present at the

Virtual Investor 2023 Companies to Watch Event

on

Wednesday, January 18, 2023

at

10:00 AM ET

.

A

live video webcast

of the presentation will be available on the

Events

page of the

Investors

section of the Company’s website (

cnspharma.com

). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.


About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

For more information, please visit

www.CNSPharma.com

, and connect with the Company on

Twitter

,

Facebook

, and

LinkedIn

.

Cision
View original content to download multimedia:

https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-virtual-investor-2023-companies-to-watch-event-301714427.html

SOURCE CNS Pharmaceuticals, Inc.

If You Liked This Article Click To Share

Biotech